secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001558370-23-003872
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte FY2022 total revenue $44.3M (+31% YoY); net loss $23.6M
---------------------------------------------------------------

- Q4 2022 revenue $12.4M (+22% YoY); core revenue $10.6M (+4%); gross margin 88%.
- Full-year core business revenue $39.6M, up 26%; cell therapy segment grew 33%.
- Net loss $23.6M vs $19.1M; EBITDA loss $24.8M; cash and equivalents $227.3M.
- 18 active SPL partnerships; potential pre-commercial milestones >$1.55B.
- 2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program revenue ~$6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023003872/0001558370-23-003872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023003872/mxct-20230315x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-003872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer